Material Modification to Rights of Security Holders

Business Context and Reporting Period

This Form 8-K is filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp) on March 23, 2020. The report details a material modification to the rights of security holders involving a reverse stock split.

Key Financial Metrics

This filing is a current report regarding corporate governance and capital structure changes. It does not provide revenue, profit, cash flow, margin, debt, or liquidity figures.

Material Changes

  • Reverse Stock Split: The Company executed a 1-for-15 reverse stock split of its issued and outstanding common stock.
  • Effective Date: The split became effective at 1:05 p.m. PT on March 24, 2020.
  • Trading Details: Common stock began trading on a split-adjusted basis on March 25, 2020, under the existing symbol EKSO on the Nasdaq Capital Market with a new CUSIP number (282644301).
  • Share Structure: Authorized shares remain at 141,428,571. Fractional shares were rounded up to the next whole share.
  • Impact on Derivatives: The split adjusted restricted stock units, stock options, and warrants outstanding prior to effectiveness.

Outlook, Risks, and Management Commentary

Purpose: The primary objective of the reverse stock split is to maintain the Company's listing on the Nasdaq Capital Market. The Company had previously received notice on September 16, 2019, of failing to meet the minimum bid price requirement.

Management View: Management believes the reduced share count will increase the per-share market price, thereby improving marketability, liquidity, and the likelihood of regaining compliance with Nasdaq listing rules.

Risks: The filing notes that the information is qualified by reference to the full text of the Amendment and the Definitive Proxy Statement filed on February 10, 2020.

Investor Verification Checklist

  • Verify the new CUSIP number (282644301) for trading purposes.
  • Confirm the adjusted share count and price per share on March 25, 2020.
  • Review the impact of the 1-for-15 ratio on outstanding options and warrants.
  • Monitor subsequent filings to confirm compliance with Nasdaq minimum bid price requirements.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.